Skip to main content
Deepa Jagadeesh, MD, Oncology, Cleveland, OH

DeepaJagadeeshMDMPH

Oncology Cleveland, OH

Cutaneous Lymphoma, Hematologic Oncology

Associate Staff, Taussig Cancer Institute, Cleveland Clinic

Dr. Jagadeesh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Jagadeesh's full profile

Already have an account?

  • Office

    9500 Euclid Ave
    Taussig Cancer Institute
    Cleveland, OH 44149
    Phone+1 216-444-0857

Education & Training

  • UMass Chan Medical School
    UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2009 - 2012
  • UMass Chan Medical School
    UMass Chan Medical SchoolResidency, Internal Medicine, 2005 - 2008
  • University of Massachusetts Medical School
    University of Massachusetts Medical SchoolInternship, Transitional Year, 2004 - 2005
  • J.J.M. Medical College
    J.J.M. Medical CollegeClass of 1996

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2012 - 2026
  • MA State Medical License
    MA State Medical License 2008 - 2012
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation  
    Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature

Abstracts/Posters

  • Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
    Deepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab
    Deepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
    Deepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Stark County Woman Shares Story of Battle with Rare Cancer to Give Others Hope
    Stark County Woman Shares Story of Battle with Rare Cancer to Give Others HopeFebruary 29th, 2020
  • Don’t Miss These Cleveland Clinic Cancer Center Presentations at the 2019 ASCO Annual Meeting
    Don’t Miss These Cleveland Clinic Cancer Center Presentations at the 2019 ASCO Annual MeetingMay 30th, 2019
  • R-EPOCH May Extend Survival in Patients with Rare Forms of Diffuse Large B-cell Lymphoma
    R-EPOCH May Extend Survival in Patients with Rare Forms of Diffuse Large B-cell LymphomaMarch 11th, 2019
  • Join now to see all